Microfluidic flow chambers offer advanced in vitro modeling of hemostasis and thrombosis, with potential future applications as clinical assays for genetic bleeding disorders.
Answers are grounded in this paper and cite their sources.
Microfluidic flow chambers enhance fidelity of human blood hemostasis studies; leaves open standardization for clinical diagnostics.
Platelet adhesion and aggregation, coagulation, fibrin formation, and fibrinolysis are regulated by the forces and flows imposed by blood at the site of a vascular injury. Flow chambers designed to observe these events are an indispensable part of doing hemostasis and thrombosis research, especially with human blood. Microfluidic methods have provided the flexibility to design flow chambers with complex geometries and features that more closely mimic the anatomy and physiology of blood vessels. Additionally, microfluidic systems with integrated optics and/or pressure sensors and on-board signal processing could transform what have been primarily research tools into clinical assays. Here, we describe a historical review of how flow-based approaches have informed biophysical mechanisms in genetic bleeding disorders, challenges and potential solutions for developing models of bleeding in vitro, and outstanding issues that need to be addressed prior to their use in clinical settings.
No takes yet. Share an insight, caveat, or question.
Schoeman et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: